Navigation Links
Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Date:4/24/2012

aboration with the UW Carbone Cancer Center," said Harry Palmin, President and CEO of Novelos. "We believe these data begin to establish proof-of-concept for LIGHT as a PET imaging agent for NSCLC, could advance our partnering discussions and could be used to calculate effective doses for Phase 2 clinical trials of I-131-CLR1404 (HOT). HOT is our chemically identical small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells."

About LIGHT
LIGHT is a small molecule imaging agent that we believe has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope. PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating broad-spectrum, cancer-selective uptake and retention.  Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing. The trials include lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors. These human trials, if successful, will serve three important purposes. First, they would provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current "gold standard" agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT's superior cancer-specificity and more favorable logistics of clinical use. Second, favorable results would advance partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical development of HOT by predic
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
2. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
3. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
4. Novelos Therapeutics Prices $5.9 Million Public Offering
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 OmniSeq, LLC today announced the ... OmniSeq SM Genomic Network.  Recently, OmniSeq officially ... and announced it was making available a suite ... approach to genomic diagnostics that provides actionable results ... a rapidly expanding, multidisciplinary cancer care center that ...
(Date:8/3/2015)... 3, 2015 According to ... Research "Global Market Study on Physiotherapy Equipment - ... Growth by 2022", the global physiotherapy equipment market is estimated ... of 2015 and is expected to grow at ... to account for US$23.7 Bn by 2022. ...
(Date:8/3/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... results for the three months ended June 30, 2015, ... upcoming milestones for its clinical development programs. ... for CytRx. Enrollment in our ongoing pivotal global Phase ... (STS) continues on track to be completed in the ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 ... leads to one pound of weight loss may not be accurate. While this system may ... one pound of fat varies – based both on the individual and at what point ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B ... B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... that while an overwhelming number of Hispanics believe people can positively affect their ... percent of participants queried said making diet changes was important. Far fewer participants ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany approach ... – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in the ... mission is to develop technology for the sake of humanity – continues to ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... insulin has been found to suppress the expression in ... pathogenesis of Alzheimer,s disease, according to new clinical research ... March online in the Journal of Clinical Endocrinology ... powerful, new role to play in fighting Alzheimer,s disease. ...
... the Centers for Disease Control and Prevention (CDC) ... (HICPAC) outline steps to eliminate bloodstream infections in ... most deadly and costly healthcare-associated infections (HAIs). ... Intravascular Catheter-Related Infections" will be published in its ...
... parents get their information about vaccines from their children,s ... parents, friends and family members and even celebrities as ... of a national survey conducted by University of Michigan ... of information in regards to vaccines, as well as ...
... 1 (HealthDay News) -- Exercise is a good way for ... says an expert. "People who have arthritis are often ... but the condition will only get worse if people don,t ... Center for Fitness in Maywood, Ill., said in a news ...
... brand new technology that promises a range of applications ... reached another world first in its development. This milestone ... and Technology Facilities Council,s (STFC) Daresbury Laboratory in Cheshire. ... start up of the pioneering EMMA accelerator which is ...
... to quickly distinguish individuals with active tuberculosis (TB) from ... the preliminary results of the study will be confirmed ... could allow more effective strategies to control the spread ... performed by a group of scientists from the Catholic ...
Cached Medicine News:Health News:Insulin could be Alzheimer's therapy 2Health News:CDC issues updated bloodstream infection prevention guidelines 2Health News:CDC issues updated bloodstream infection prevention guidelines 3Health News:U-M experts: Parents trust doctors most when it comes to information about vaccine safety 2Health News:Exercise Is Key for People With Arthritis: Expert 2Health News:EMMA milestone beams its way to a world first 2Health News:EMMA milestone beams its way to a world first 3Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 2Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: